Journal
CLINICAL CANCER RESEARCH
Volume 27, Issue 4, Pages 913-915Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-20-3914
Keywords
-
Categories
Funding
- Cancer Prevention and Research Institute of Texas Individual Investigator Research Award [RP200287, P50-CA70907-21]
- Rexanna's Foundation for Fighting Lung Cancer
Ask authors/readers for more resources
Transcriptional profiling identified three robust subtypes of nonsquamous non-small cell lung cancer, regardless of initiating oncogenic driver events. Differential sensitivity to MEK 1/2 inhibitors was reported among the subtypes, and an interaction involving the mucinous subtype, STKII/LKBI genomic alterations, and inferior clinical outcomes with atezolizumab in the OAK clinical trial was identified.
Using transcriptional profiling, three robust subtypes of nonsquamous non-small cell lung cancer were defined, independently of initiating oncogenic driver events. Subtype-specific differential sensitivity to MEK 1/2 inhibitors was reported and an interaction between the mucinous subtype, STKII/LKBI genomic alterations, and inferior clinical outcomes with atezolizumab in the OAK clinical trial was identified.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
